SecBot SecBot

RLMD drug pipeline

$3.61
−14.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 2 completed; preparing for Phase 3 (SPECTRUM program)
Time to marketIf the IND is cleared by early 2027 and Phase 3 SPECTRUM program proceeds smoothly, potential FDA submission could be 2029-2030, assuming positive pivotal data. The drug is still pre-Phase 3.

NDV-01 Updated Nov 15

What to watch

The next catalyst is the NDV-01 IND submission, which Relmada expects by year-end 2026 (about 6 weeks away). A successful IND clearance would allow the Phase 3 SPECTRUM program to begin, while any delay or FDA clinical hold would be sharply negative. The Q4 2026 corporate update will likely confirm the submission status.

Bull case
  • Phase 2 data showed a 76% durable complete response rate at 12 months in NMIBC, with 86% of 12-month complete responders maintaining response at 18 months, suggesting a durable treatment effect.
  • Relmada has a strong cash position of $202.1M (Q3 2026), expected to fund operations through 2029, removing near-term financing risk.
  • CEO Sergio Traversa and CFO Maged Shenouda collectively purchased ~$1.67M of stock in open-market transactions in September 2026, a strong insider conviction signal.
Bear case
  • Relmada has no approved products or revenue; it is entirely dependent on NDV-01 clinical trial success after its prior lead drug REL-1017 failed Phase 3 in depression (2022/2024), causing an 80% stock drop in December 2024.
  • The Phase 2 data showed two BCG-naive patients progressed to muscle-invasive disease at Month 15, a potential safety signal that could complicate FDA review.
  • The company has massively diluted shareholders: shares outstanding grew from ~30M at end-2024 to ~105M by May 2026, and an S-3 shelf registration filed in May 2026 signals potential further dilution.